Belfast, U.K. – 18 September, 2018.
CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, announced today that Dr. Robert Ladner, CEO and Founder, was invited to present the Company’s ground-breaking research that led to the development of the novel dUTPase inhibitor and clinical drug candidate CV6-168 at the 22nd International Charles Heidelberger Symposium on Cancer Research in Tomsk, Russia in September 2018. The Charles Heidelberger Symposium is a cancer research symposium organized annually to honour and commemorate the late Prof. Charles Heidelberger, former president of the American Association for Cancer Research, member of the National Academy of Sciences of the U.S.A., and an extraordinary scientist and pioneer in the fields of carcinogenesis and cancer chemotherapy. Most notably Charles is credited with the discovery of the fluoropyrimidine 5-fluorouracil (5-FU), the first example of a rationally-designed cancer drug and arguably the most widely used cancer therapy in history. In 2018, 5-FU and its subsequent formulations remain front-line agents worldwide in the treatment of numerous solid tumour types including gastrointestinal cancers, lung and breast cancers.
The Heidelberger Symposium brings together scientists from around the world to present their achievements and discuss the most recent advances in cancer, from basic research to clinical applications. Dr Ladner delivered a presentation on CV6-168 entitled “Development and Characterization of CV6-168, a Novel and Selective dUTPase Inhibitor that Enhances the Antitumour Efficacy of TS-targeted Therapies”. CV6-168 is the most advanced therapeutic in the CV6 pipeline and represents a new anticancer therapeutic that is rationally-designed to work alongside 5-FU and other TS-targeted drugs such as pemetrexed to significantly enhance their anticancer activity and improve patient outcome.
Robert Ladner commented:
“I’m deeply honoured for this incredible opportunity to present our research at such a prestigious event that celebrates the life and work of Heidelberger, a true pioneer and innovator of cancer therapeutics but also to share the stage with cancer researchers from across the world, the modern day innovators of cancer research, who continue to build upon these early discoveries and make advances in the fight against this deadly disease”
The Symposium took place in the Oval Hall of the National Research Tomsk State University in Russia on September 17th. One of Siberia’s oldest cities, Tomsk was founded in 1604 and is dubbed the ‘cultural capital of Siberia’ with its grand University and well-preserved late-19th- and early-20th-century ‘wooden-lace’ architecture.
CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. To learn more about CV6 Therapeutics and its product pipeline including CV6-168, click here: CV6 Therapeutics.